Affimed N.V. announced interim safety and efficacy data on its innate cell engager (ICE(R) AFM24 from the ongoing AFM24-102 combination study with atezolizumab, an anti-PD-L1 checkpoint inhibitor, in patients with advanced EGFR-expressing solid tumors. The data update as of December 6(th), 2023, includes 15 patients from the EGFR- wildtype NSCLC cohort with a median of 2 prior lines of therapy. The Company also announced data from the phase 1/2 data study of acimtamig in combination with allogeneic NK in relapsed/refractory Hodgkin Lymphoma patients conducted at the University of Texas MD Anderson Cancer Center.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.23 USD | 0.00% | -2.24% | -16.32% |
04-01 | Wells Fargo Cuts Affimed Price Target to $25 From $30, Maintains Overweight Rating | MT |
04-01 | HC Wainwright Adjusts Affimed's Price Target to $10 From $50, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.32% | 79.64M | |
+2.93% | 106B | |
+7.02% | 23.47B | |
-14.60% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-8.83% | 16.78B | |
+5.51% | 14.41B | |
+37.49% | 12.86B | |
+329.39% | 8.78B |
- Stock Market
- Equities
- AFMD Stock
- News Affimed N.V.
- Affimed N.V. Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-Treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients